Close Menu

NEW YORK – HTG Molecular Diagnostics reported after the close of the market on Tuesday that its third quarter revenues grew 15 percent year over year as product-related revenues more than offset a decline in collaborative revenues.

The company also said that it has terminated a companion diagnostic development deal with Qiagen in the wake of that company's discontinuation of next-generation sequencing instruments, causing HTG to also reduce its full-year 2019 revenue guidance.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.